Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, has closed its latest early-stage healthcare venture capital fund, Sofinnova Capital X, oversubscribed at EUR472 million (USD548 million).
Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, has closed its latest early-stage healthcare venture capital fund, Sofinnova Capital X, oversubscribed at EUR472 million (USD548 million).
This brings the total amount the VC has raised to EUR1 billion in the last 12 months across its multi-fund platform, and the total AUM to over EUR2.5 billion. Capital X, the 10th iteration of Sofinnova Partners’ flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.
Sofinnova Capital X will invest in the most promising biopharmaceutical and medical device start-ups that address pressing unmet clinical needs and aim to transform patients’ lives. In keeping with the current strategy, the team will source and create value across a portfolio of groundbreaking innovations in healthcare, supporting entrepreneurs globally in the creation and growth of their companies.
Capital X was successfully raised with institutional investors including pension funds, insurance companies, foundations, endowments, corporate investors, and prominent family offices from across Europe, Asia, and North America. The Fund welcomed back existing investors and attracted new blue chip limited partners, reflecting sustained confidence in the firm’s capacity to generate strong financial returns.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, says: “The close of Capital X, significantly oversubscribed and raised in record time, comes at a pivotal moment as the importance of healthcare innovation has become exceedingly clear to all. The fact we have been able to raise EUR1 billion across our platform over the past 12 months is a tribute to our investors and their conviction in our ability to bolster our leading position in Europe.”
Henrijette Richter, Managing Partner of Sofinnova Partners, says: “We are thrilled to have raised the largest fund dedicated to early-stage healthcare investments in Europe. This is an important milestone for Sofinnova Partners. Capital X will allow us to leverage over 30 years of cumulative experience perfecting this strategy. We now have more capital than ever to support leading entrepreneurs as they launch new companies to develop groundbreaking therapies that have the potential to change peoples’ lives.”
Clifford Chance acted as legal counsel and Triago as placement agent.
